Publication
An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
Authors not recorded
Eur J Endocrinol2022PMID 35118995stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerThyroid Gland Papillary Carcinomacivic_curation1.00
- drugLarotrectinibcivic_curation1.00
- geneNTRK1civic_curation1.00
- variantNTRK1 Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 35118995
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NTRK1 Fusion1 | ||||||||
| Larotrectinib | Thyroid Gland Papillary CarcinomaALIAS | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID11575Bragas et al (2022) report a case study of a 50-year old female with a papillary thyroid carcinoma with multiple metastases containing a SQSTM1::NTRK1 fusion treated with larotrectinib. SQSTM1::NTRK1 … (full text at CIViC) PMID 35118995 · Bargas et al., 2022 · Open in CIViC | civic |